18 results about "Multipotent Stem Cell" patented technology

A cell population comprising Corin- and / or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and / or Lrtm1 positive cells are collected using a substance that binds to Corin and / or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and / or Lrtm1 positive cells in a culture solution containing one or more nutritional factors:(1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and(2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Described herein are compositions and methods for modifying eukaryotic cells, for example, to express a transgene of interest and / or to produce an expanded population of cells ex vivo. Using the compositions and methods of the disclosure, a population of eukaryotic cells, such as a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) may be transduced to express a gene of interest by contacting the cells with a viral vector, such as a lentiviral vector, and a poloxamer. Additionally, the compositions and methods described herein can be used to promote the proliferation or survival of a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) ex vivo, for example, by contacting the cells with a poloxamer. Examples of poloxamers that may be used in conjunction with the compositions and methods of the disclosure are those having a molar mass in excess of 10,000 g / mol, as well as those having a molar mass of polyoxypropylene subunits greater than 2,000 g / mol and / or an ethylene oxide content of greater than 40% by mass.

This disclosure relates to a method for producing induced midbrain dopaminergic progenitor cells (imDAPs) that can provide high imDAP cell differentiation efficiency. This disclosure also provides a substantially homogeneous imDAP cell population.

The present invention relates to methods and compositions for inducing differentiation of hematopoietic cells. The present invention provides culture platforms, cell culture media, and methods for differentiating pluripotent cells into hematopoietic cells. The present invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein that allow for feeder cell-free monolayer culture without EB formation. In particular, the pluripotent stem cell-derived hematopoietic cells of the present invention include, and are not limited to, iHSCs, permanent hemogenic endothelial cells, hematopoietic multipotent progenitor cells, T cell progenitor cells, NK cell progenitor cells, T cells, NK cells, NKT cells, and B cells.

Methods and compositions are provided for obtaining functionally enhanced induced effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable, functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and uses thereof are also provided, comprising the functionally enhanced induced effector cells alone or in combination with antibodies or checkpoint inhibitors in combination therapy.

Disclosed herein is a method of identifying an arrhythmogenic pluripotent stem cell-derived cardiomyocyte (PSC-CM), the method comprising: (i) determining whether CD200 is expressed on a surface of the PSC-CM; wherein if CD200 is expressed on the surface of the PSC-CM, the PSC-CM is an arrhythmogenic PSC-CM.

This invention belongs to the field of regenerative medicine and relates to cell therapy, specifically providing pluripotent stem cell-derived RPE cells, formulations, pharmaceutical compositions, reagents, methods, and kits. Obtaining RPE cells by differentiation of iPSCs is achieved by adding small chemical molecules as inhibitors or activators to E6 medium and includes a neuroectoderm cell induction phase, an RPE progenitor cell induction phase, an RPE cell induction phase, and an RPE cell maturation phase. In this differentiation process, there is no need to manually remove heterogeneous cells with non-RPE-like morphology, and pure RPE cells can be obtained by subculturing.

The invention provides a method of generating retinal pigmented epithelial (RPE) cells from pluripotent stem cells (PSCs), and methods of use of the cells. The disclosure provides a method of generating RPE cells by differentiation of PSCs and includes the treatment of PSCs with one or more of a transforming growth factor β / SMAD2 / SMAD3 pathway signaling inhibitor, a bone morphogenetic protein / SMAD1 / SMAD5 / SMAD8 pathway signaling inhibitor or a fibroblast growth factor / ERK pathway signaling inhibitor, and a TGFβ family protein. Use of such RPE cells include methods of treating macular degeneration by administering the RPE cells to a subject in need thereof.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

This article provides a thermally reversible polymer with improved stability, a hydrogel composition comprising the thermally reversible polymer, and an in vitro method for generating a cell population rich in inhibitory GABAergic cortical interneurons from human pluripotent stem cells using the hydrogel composition.

Described herein are methods and culture medium, useful for inducing polarization in multipotent stem cells. Additionally, described herein are multipotent cells produced by the methods and culture medium of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells that are produced by the methods and culture medium of this disclosure that are useful as therapeutic agents.

The present application discloses a method for producing dopaminergic neurons from human stem cells by adding or increasing the vitamin concentration in neurobasal medium around day 20±3 of the protocol for differentiating pluripotent stem cells into dopaminergic neurons.

An object of the present invention is to provide a method and a reagent for detecting an undifferentiated pluripotent stem cell(s). The object is achieved by being able to detect a few residual undifferentiated pluripotent stem cells through measurement of the level of RNA expressed from the MIR302CHG gene.

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and / or in / dels in one or more selected endogenous genes.